Publication:
Treatment outcomes of metastasis-directed treatment using(68)Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002)

dc.contributor.coauthorHurmuz, Pervin
dc.contributor.coauthorOnal, Cem
dc.contributor.coauthorOzyigit, Gokhan
dc.contributor.coauthorIgdem, Sefik
dc.contributor.coauthorAtalar, Banu
dc.contributor.coauthorSayan, Haluk
dc.contributor.coauthorAkgun, Zuleyha
dc.contributor.coauthorKurt, Meral
dc.contributor.coauthorOzkok, Hale Basak
dc.contributor.coauthorOymak, Ezgi
dc.contributor.coauthorTilki, Burak
dc.contributor.coauthorGuler, Ozan Cem
dc.contributor.coauthorMustafayev, Teuto Zoto
dc.contributor.coauthorSaricanbaz, Irem
dc.contributor.coauthorRzazade, Rashad
dc.contributor.coauthorAkyol, Fadil
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorSelek, Uğur
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:37:48Z
dc.date.issued2020
dc.description.abstractPurpose The aim of this study was to evaluate the outcomes of(68)Ga prostate-specific membrane antigen (Ga-68-PSMA) positron-emission tomography (PET)/CT-based metastasis-directed treatment (MDT) for oligometastatic prostate cancer (PC). Methods In this multi-institutional study, clinical data of 176 PC patients with 353 lesions receiving MDT between 2014 and 2019 were retrospectively evaluated. All patients had biopsy proven PC with <= 5 metastases detected with(68)Ga-PSMA-PET/CT. MDT was delivered with conventional fractionation or stereotactic body radiotherapy (SBRT) techniques. CTCAE v4.0 was used for acute and RTOG/EORTC Late Radiation Morbidity Scoring Schema was used for late toxicity evaluation. Results At the time of MDT, 59 patients (33.5%) had synchronous and 117 patients (66.5%) had metachronous metastases. Median number of metastases was one and the MDT technique was SBRT in 73.3% patients. The 2-year overall survival (OS) and progression-free survival (PFS) rates were 87.6% and 63.1%, respectively. With a median follow-up of 22.9 months, 9 patients had local recurrence at the irradiated site. The 2-year local control rate at the treated oligometastatic site per patient was 93.2%. In multivariate analysis, an increased number of oligometastases and untreated primary PC were negative predictors for OS; advanced clinical tumor stage, untreated primary PC, BED3 value of <= 108Gy, and MDT with conventional fractionation were negative predictors for PFS. No patient experienced grade >= 3 acute toxicity, but one patient had a late grade 3 toxicity of compression fracture after spinal SBRT. Conclusion Ga-68-PSMA-PET/CT-based MDT is an efficient and safe treatment for oligometastatic PC patients. Proper patient selection might improve treatment outcomes.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue11
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume196
dc.identifier.doi10.1007/s00066-020-01660-6
dc.identifier.eissn1439-099X
dc.identifier.issn0179-7158
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85087421488
dc.identifier.urihttps://doi.org/10.1007/s00066-020-01660-6
dc.identifier.urihttps://hdl.handle.net/20.500.14288/12869
dc.identifier.wos545850300001
dc.keywordsProstate adenocarcinoma
dc.keywordsStereotactic body radiotherapy
dc.keywordsPSMA PET
dc.keywordsOligometastasis
dc.keywordsSurvival Stereotactic body radiotherapy
dc.keywordsCurative treatment
dc.keywordsRecurrence
dc.keywordsTherapy
dc.keywordsPET/CT
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofStrahlentherapie und Onkologie
dc.subjectOncology
dc.subjectRadiology, Nuclear Medicine and medical imaging
dc.titleTreatment outcomes of metastasis-directed treatment using(68)Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002)
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorSelek, Uğur
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files